Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AtriCure Inc Raises FY 2013 Revenue Guidance; Reaffirms FY 2013 EBITDA Guidance


Thursday, 1 Aug 2013 04:03pm EDT 

AtriCure Inc announced that for fiscal 2013, it expects revenue to be in the range of $77.0 - $78.5 million, as compares to the previous outlook for fiscal 2013 revenue in the range of $76.5-$78.0 million. Adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of $3.0 to $5.0 million including the impact of the medical device excise tax which is estimated to be in the range of $0.8 - $1.0 million for fiscal 2013. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $77.7 million for fiscal 2013. 

Company Quote

15.04
-0.08 -0.53%
16 Sep 2014